Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: A retrospective study

被引:56
作者
Cannady, SB
Cavanaugh, KA
Lee, SY
Bukowski, RM
Olencki, TE
Stevens, GHJ
Barnett, GH
Suh, JH
机构
[1] Cleveland Clin Fdn, Brain Tumor Inst, Dept Radiat Oncol, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Brain Tumor Inst, Dept Otolaryngol, Cleveland, OH 44195 USA
[3] Cleveland Clin Fdn, Brain Tumor Inst, Dept Med Oncol, Cleveland, OH 44195 USA
[4] Cleveland Clin Fdn, Brain Tumor Inst, Dept Neurol, Cleveland, OH 44195 USA
[5] Cleveland Clin Fdn, Brain Tumor Inst, Dept Neurosurg, Cleveland, OH 44195 USA
[6] Wake Forest Univ, Sch Med, Dept Psychiat, Winston Salem, NC 27109 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2004年 / 58卷 / 01期
关键词
brain metastases; renal cell cancer; whole brain radiation therapy;
D O I
10.1016/S0360-3016(03)00818-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the benefit of whole brain radiotherapy (WBRT) and the use of the Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) classification system in patients with brain metastases from renal cell carcinoma. Methods and Materials: We identified 46 consecutive patients with brain metastases from renal cell carcinoma who were treated with WBRT at the Cleveland Clinic Foundation between 1983 and 2000. We reviewed their charts for patient and tumor characteristics and categorized them according to the RTOG RPA classes. Results: The median follow-up and survival time for all 46 patients (15 women and 31 men) was 3.0 months. The median radiation dose was 3000 cGy in 10 fractions. Patients who received higher radiation doses (>3000 cGy) survived longer than those who received 3000 cGy or less than 3000 cGy (8.5 months vs. 2.7 months vs. 0.4 months, p = 0.0289). However, the Karnofsky performance status and RPA class were confounding factors in these data. The median survival for patients by RTOG RPA class was 8.5 months for Class I (n = 2), 3 months for Class II (n = 37), and 0.6 months for Class III (n = 7, p = 0.0834). Conclusion: Despite the relatively poor prognosis of patients who receive WBRT alone, it appears that they benefit from this palliative treatment. The RTOG RPA classification system may be a useful tool in assessing prognosis in this patient population. (C) 2004 Elsevier Inc.
引用
收藏
页码:253 / 258
页数:6
相关论文
共 33 条
  • [11] The role of whole brain radiotherapy and stereotactic radiosurgery on brain metastases from renal cell carcinoma
    Goyal, LK
    Suh, JH
    Reddy, CA
    Barnett, GH
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (04): : 1007 - 1012
  • [12] HALPERIN EC, 1983, CANCER-AM CANCER SOC, V51, P614, DOI 10.1002/1097-0142(19830215)51:4<614::AID-CNCR2820510411>3.0.CO
  • [13] 2-J
  • [14] MANAGEMENT OF METASTASES TO BRAIN BY IRRADIATION AND CORTICOSTEROIDS
    HORTON, J
    BAXTER, DH
    OLSON, KB
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY RADIUM THERAPY AND NUCLEAR MEDICINE, 1971, 111 (02): : 334 - &
  • [15] THE PALLIATION OF BRAIN METASTASES IN A FAVORABLE PATIENT POPULATION - A RANDOMIZED CLINICAL-TRIAL BY THE RADIATION-THERAPY ONCOLOGY GROUP
    KURTZ, JM
    GELBER, R
    BRADY, LW
    CARELLA, RJ
    COOPER, JS
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1981, 7 (07): : 891 - 895
  • [16] Lang FF, 1998, SEMIN SURG ONCOL, V14, P53
  • [17] MAOR MH, 1988, CANCER, V62, P1912, DOI 10.1002/1097-0142(19881101)62:9<1912::AID-CNCR2820620908>3.0.CO
  • [18] 2-T
  • [19] TREATMENT FOR PATIENTS WITH CEREBRAL METASTASES
    MARKESBERY, WR
    BROOKS, WH
    GUPTA, GD
    YOUNG, AB
    [J]. ARCHIVES OF NEUROLOGY, 1978, 35 (11) : 754 - 756
  • [20] Mori Y, 1998, CANCER-AM CANCER SOC, V83, P344, DOI 10.1002/(SICI)1097-0142(19980715)83:2<344::AID-CNCR19>3.0.CO